title: A rat model of studying tissue-type plasminogen activator thrombolysis in ischemic stroke with diabetes.
abstract: OBJECTIVE
  Poststroke hyperglycemia and diabetes mellitus are associated with lower thrombolytic efficacy and an increased risk of postischemic cerebral hemorrhage. We aimed to develop a rodent model of thrombolysis in diabetic stroke that mimics the clinical situation.  Method- Male 6-week Type I diabetic rats (14 weeks old) were subjected to embolic focal stroke and treated with tissue-type plasminogen activator at 1.5 hours. Reperfusion and 24-hour neurological outcomes were measured and compared with nondiabetic control rats.
  
  
  RESULTS
  Diabetic rats exhibited resistance to thrombolytic reperfusion, larger infarction volumes, and increased intracerebral hemorrhage.
  
  
  CONCLUSIONS
  This animal model would be relevant to future studies investigating pathophysiological mechanisms and in developing new therapeutic approaches to enhance the efficacy of tissue-type plasminogen activator thrombolysis in stroke patients with diabetes or poststroke hyperglycemia.
authors: Neuroprotection Research Laboratory, Department of Neurology and Radiology, Massachusetts General Hospital, Neuroscience Program, Harvard Medical School, Boston, MA 02129, USA.
authors: Xiang
authors: X
authors: Fan
authors: Jianhua
authors: J
authors: Qiu
authors: Zhanyang
authors: Z
authors: Yu
authors: Haibin
authors: H
authors: Dai
authors: Aneesh B
authors: AB
authors: Singhal
authors: Eng H
authors: EH
authors: Lo
authors: Xiaoying
authors: X
authors: Wang
mesh_terms: D000818:Animals; D001929:Brain Edema / Q000188:drug therapy / Q000473:pathology; D002545:Brain Ischemia / Q000150:complications / Q000188:drug therapy*; D002543:Cerebral Hemorrhage / Q000188:drug therapy / Q000473:pathology; D002544:Cerebral Infarction / Q000188:drug therapy / Q000473:pathology; D003921:Diabetes Mellitus, Experimental / Q000150:complications; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced / Q000150:complications; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D007150:Immunohistochemistry; D020766:Intracranial Embolism / Q000188:drug therapy / Q000473:pathology; D017078:Laser-Doppler Flowmetry; D008297:Male; D008833:Microcirculation / Q000502:physiology; D009422:Nervous System Diseases / Q000209:etiology; D051381:Rats; D017208:Rats, Wistar; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D005343:Fibrinolytic Agents; D010959:Tissue Plasminogen Activator